EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.54), $0.02 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.06 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 22nd Century Group files prospectus for warrant share resale
• MagnaChip (MX) files $50M mixed shelf